Cargando…
Pregnancy outcomes following exposure to onabotulinumtoxinA
PURPOSE: To evaluate pregnancy outcomes following onabotulinumtoxinA (US Food and Drug Administration pregnancy category C product) exposure using the Allergan safety database. METHODS: The Allergan Global Safety Database contains reports of onabotulinumtoxinA administration before/during pregnancy,...
Autores principales: | Brin, Mitchell F., Kirby, Russell S., Slavotinek, Anne, Miller‐Messana, Mary Ann, Parker, Lori, Yushmanova, Irina, Yang, Huiying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063122/ https://www.ncbi.nlm.nih.gov/pubmed/26635276 http://dx.doi.org/10.1002/pds.3920 |
Ejemplares similares
-
Pregnancy Outcomes in Patients Exposed to OnabotulinumtoxinA Treatment: A Cumulative 29-Year Safety Update
por: Brin, Mitchell F., et al.
Publicado: (2023) -
Botox (onabotulinumtoxinA) mechanism of action
por: Brin, Mitchell F., et al.
Publicado: (2023) -
Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA
por: Ayyoub, Ziyad, et al.
Publicado: (2020) -
The pluripotential evolution and journey of Botox (onabotulinumtoxinA)
por: Brin, Mitchell F., et al.
Publicado: (2023) -
Safety of OnabotulinumtoxinA with Concomitant Antithrombotic Therapy in Patients with Muscle Spasticity: A Retrospective Pooled Analysis of Randomized Double-Blind Studies
por: Dimitrova, Rozalina, et al.
Publicado: (2020)